Legend Biotech Corp Increase Decrease In Cash And Cash Equivalents
Legend Biotech Corp (LEGN) reported Increase Decrease In Cash And Cash Equivalents of $615.20 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2026-03-10
- Legend Biotech Corp increase decrease in cash and cash equivalents for the quarter ending 2025-12-31 was $623.06M.
- Legend Biotech Corp increase decrease in cash and cash equivalents for the quarter ending 2024-12-31 was -$172.56M.
| Period end | Increase Decrease In Cash And Cash Equivalents 3 month | Increase Decrease In Cash And Cash Equivalents 9 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|---|
| 2025-12-31 | $623.06M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $615.20M 20-F · filed 2026-03-10 | |
| 2025-09-30 | -$7.86M 6-K · filed 2025-11-12 | ||
| 2024-12-31 | -$172.56M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$991.00M 20-F · filed 2026-03-10 | |
| 2024-09-30 | -$818.44M 6-K · filed 2025-11-12 | ||
| 2023-12-31 | $491.70M 20-F · filed 2026-03-10 |